メニュー
Domain-validated decision logic for optogenetic stimulation parameter selection, including opsin choice, light delivery, pulse protocols, fiber placement, and control conditions
デフォルトでは、最初にソースを確認する Prompt が選択されています。直接コマンドに切り替えるか、ローカルコピーをダウンロードすることもできます。
インストールを決める前に、SKILL.md と SkillsMP に表示されている付属ファイルをお読みください。
SOC 職業分類に基づく
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
直接コマンドでは確認用 Prompt が省略されます。実行前にソースを確認してください。
npx skills add https://github.com/NeuroAIHub/BrainPilot --skill optogenetics-protocol-designerコマンドは1行のまま表示されます。コピー前に横へスクロールして全体を確認してください。
ローカルで確認しますか？SkillsMP が現在取得できるファイルをダウンロードできます。
SKILL.md を表示中
Audit scientific implementation, exported-model equivalence, dependency completeness, manifests, packaging, and isolated inference. Use when claims depend on code, trained artifacts, evaluators, or deployable entry points.
Audit scientific data semantics, sample and label alignment, leakage, group splits, preprocessing boundaries, and train-to-inference transforms. Use for any result based on datasets, feature matrices, tensors, repeated observations, or learned preprocessing.
Audit numeric, artifact, log, citation, and cross-report claims against inspectable evidence. Use for reports, syntheses, benchmark claims, external citations, or conflicting Expert outputs.
| name | optogenetics-protocol-designer |
| description | Domain-validated decision logic for optogenetic stimulation parameter selection, including opsin choice, light delivery, pulse protocols, fiber placement, and control conditions |
| domain | cellular-molecular-neuroscience |
| authors | ["Claude (AI-assisted synthesis)"] |
| version | 1.0.0 |
| papers | ["Deisseroth, 2015","Fenno, Yizhar & Deisseroth, 2011","Yizhar, Fenno, Davidson, Mogri & Deisseroth, 2011","Mattis et al., 2012","Aravanis et al., 2007"] |
| dependencies | {"required":["research-literacy"]} |
| review_status | ai-generated |
Optogenetic protocol design requires domain expertise that a general-purpose programmer would systematically get wrong. Selecting an opsin is not like selecting a software library — it requires understanding photocycle kinetics, ion selectivity, spectral overlap, expression toxicity, and the biophysics of light propagation through neural tissue. A naive approach risks tissue damage from heating, silencing neurons you intended to activate (depolarization block), or producing uninterpretable results from inadequate controls. This skill encodes the decision logic that bridges the gap between "I want to activate neurons" and a rigorous, publishable optogenetic protocol.
Before executing the domain-specific steps below, you MUST:
For detailed methodology guidance, see the research-literacy skill.
This skill was generated by AI from academic literature. All parameters, thresholds, and citations require independent verification before use in research. If you find errors, please open an issue.
| Goal | Category | Key Constraint |
|---|---|---|
| Drive action potentials with millisecond precision | Excitation (fast) | Need opsin with tau-off < 15 ms |
| Sustained depolarization / increased excitability | Excitation (tonic) | Step-function opsin or low-frequency pulsed |
| Silence neurons during a behavioral epoch | Inhibition (sustained) | Need potent inhibitory opsin, manage heating |
| Brief synaptic suppression | Inhibition (phasic) | Fast inhibitory opsin, short pulses |
| Bidirectional control in same animal | Dual manipulation | Spectrally separated opsins required |
| Opsin | Peak lambda | Tau-off | Photocurrent | Best For | Key Citation |
|---|---|---|---|---|---|
| ChR2 (H134R) | 470 nm | ~10 ms | Moderate | Standard activation, well-characterized | Boyden et al., 2005; Nagel et al., 2005 |
| ChETA (E123T) | 470 nm | ~3 ms | Lower | High-frequency spiking (>40 Hz) | Gunaydin et al., 2010 |
| ChrimsonR | 630 nm | ~15 ms | Moderate | Red-shifted, deep tissue, dual-color | Klapoetke et al., 2014 |
| ChRmine | 520-530 nm | ~60 ms | Very high | Ultra-sensitive, large volume activation | Marshel et al., 2019 |
| CheRiff | 460 nm | ~8 ms | ~2x ChR2 | All-optical electrophysiology | Hochbaum et al., 2014 |
| C1V1(TT) | 540 nm | ~50 ms | Moderate | Red-shifted, combinatorial experiments | Yizhar et al., 2011 |
| Opsin | Peak lambda | Mechanism | Photocurrent | Best For | Key Citation |
|---|---|---|---|---|---|
| eNpHR3.0 | 590 nm | Cl- pump | Low (pump) | Established inhibition, yellow-light | Gradinaru et al., 2010 |
| eArch3.0 | 520-550 nm | H+ pump | Moderate (pump) | Green-light inhibition | Chow et al., 2010; Mattis et al., 2012 |
| stGtACR2 | 480 nm | Anion channel | Very high | Most potent somatic inhibition | Mahn et al., 2018 |
| SwiChR++ | 480 nm | Anion channel (bistable) | Moderate | Sustained inhibition, low light | Berndt et al., 2016 |
| Opsin | Activation | Deactivation | Tau-off (dark) | Best For | Key Citation |
|---|---|---|---|---|---|
| SSFO | Blue (~470 nm) | Yellow (~590 nm) | ~29 min | Sustained excitability increase | Yizhar et al., 2011 |
| SOUL | Blue (~470 nm) | Yellow (~590 nm) | ~29 min | Transcranial, minimally invasive | Gong et al., 2020 |
| SwiChR++ | Blue (~480 nm) | Red (~600 nm) | ~115 s | Bistable inhibition | Berndt et al., 2016 |
See references/opsin-catalog.md for the complete opsin reference with detailed kinetics.
CRITICAL — Tissue Heating Threshold:
Match the laser/LED wavelength to the opsin's absorption peak:
| Opsin Class | Recommended Wavelength | Common Laser Lines |
|---|---|---|
| ChR2 / CheRiff / stGtACR2 | 450-490 nm | 473 nm |
| C1V1 / ChRmine / eArch3.0 | 520-560 nm | 532 nm, 561 nm |
| eNpHR3.0 | 570-600 nm | 594 nm |
| ChrimsonR | 600-650 nm | 638 nm |
See references/stimulation-parameters.md for complete pulse protocol recipes.
| Opsin | Max Reliable Spike Rate | Notes |
|---|---|---|
| ChR2 (H134R) | ~30-40 Hz sustained | Fails above gamma range in sustained trains (Mattis et al., 2012) |
| ChETA | ~100-200 Hz | Reduced photocurrent trade-off (Gunaydin et al., 2010) |
| ChrimsonR | ~20-30 Hz | Slower kinetics than ChR2 (Klapoetke et al., 2014) |
| ChRmine | ~50 Hz (80 Hz with hsChRmine) | Large photocurrent compensates for slower kinetics (Marshel et al., 2019) |
| Chronos | ~100 Hz | Fastest known excitatory opsin (Klapoetke et al., 2014) |
| Parameter | Standard Value | Rationale |
|---|---|---|
| Core diameter | 200 um (mice), 200-400 um (rats/primates) | Balances illumination volume vs. tissue damage (Aravanis et al., 2007) |
| Numerical aperture (NA) | 0.22 or 0.39 | 0.22 for focused beam; 0.39 for wider illumination |
| Fiber type | Multimode step-index | Standard for optogenetics (Sparta et al., 2012) |
| Ferrule diameter | 1.25 mm (standard) or 2.5 mm | Compatibility with patch cables and commutators |
Placement rule: Position the fiber tip 200-500 um above the target region to allow light cone to cover the structure while avoiding mechanical damage to the target itself (Yizhar et al., 2011).
A rigorous optogenetic experiment requires AT MINIMUM three of the following controls (Fenno et al., 2011):
| Control | What It Rules Out | Implementation |
|---|---|---|
| Opsin-negative + light | Heating, visual, auditory artifacts from light | Inject control virus (e.g., AAV-hSyn-eYFP), deliver identical light |
| Opsin-positive + no light | Effects of viral expression alone | Implant fiber, run behavioral protocol without laser |
| Wavelength control | Non-specific photic effects | Deliver light at a wavelength outside the opsin's activation spectrum |
| Fiber implant only | Mechanical damage effects | Implant fiber without virus injection |
| Within-subject light-off epochs | Temporal confounds | Interleave light-on and light-off trials within sessions |
The single most common critique of optogenetic studies is inadequate controls. The opsin-negative + light control is non-negotiable (Fenno et al., 2011).
At high ChR2 expression levels or with prolonged/high-frequency stimulation, excessive cation influx causes sustained depolarization that inactivates sodium channels, STOPPING action potentials (Herman et al., 2014; Lin et al., 2009). This is especially dangerous with interneurons, which enter depolarization block more readily than pyramidal cells.
Signs: Loss of spiking after initial pulses in a train; behavioral effect opposite to prediction. Prevention: Limit pulse width to 1-5 ms; keep frequency at or below 40 Hz for ChR2; titrate expression levels; use ChETA for high-frequency applications.
Continuous illumination at high power heats tissue, altering neuronal firing even without opsin expression (Owen et al., 2019; Christie et al., 2013). Blue light (473 nm) is worse than red (638 nm) for heating.
Prevention: Use pulsed (not continuous) light; keep duty cycle below 40% at moderate power; use temperature modeling (Stujenske et al., 2015); always include opsin-negative light controls.
High viral titers (>1e13 vg/mL) can cause cytotoxicity, especially with prolonged expression times (>8 weeks) (Miyashita et al., 2013). Overexpression of membrane proteins disrupts normal cell physiology.
Prevention: Use titers of 1e12 to 5e12 vg/mL for standard applications; check for cell health at the injection site post-mortem; limit expression time to 3-6 weeks for most applications.
Light can scatter back up the fiber and illuminate unintended brain regions above the target. This is especially problematic for superficial targets near the brain surface.
Prevention: Use opaque ferrule sleeves; verify illumination volume with computational modeling; consider tapered fibers for focal illumination.
When inhibitory opsins (especially GtACR2, not soma-targeted) are expressed in axons, blue light can cause depolarization at the axon initial segment, producing paradoxical excitation (Mahn et al., 2018).
Prevention: Use soma-targeted variants (stGtACR2) for inhibition; avoid illuminating axon terminals with anion channelrhodopsins; verify with electrophysiology.
Prolonged eNpHR3.0 activation loads neurons with chloride, shifting the GABA-A reversal potential and causing rebound excitation upon light offset (Raimondo et al., 2012).
Prevention: Limit continuous NpHR activation to <15 seconds; use pulsed protocols for longer inhibition; consider anion channels (stGtACR2) for sustained inhibition.
| Serotype | Tropism | Onset | Spread | Use Case |
|---|---|---|---|---|
| AAV1 | Broad neuronal | 1-2 weeks | Large | General transduction (Aschauer et al., 2013) |
| AAV2 | Neuronal (restricted) | 2-4 weeks | Small | Precise local targeting |
| AAV5 | Neurons + glia | 2-4 weeks | Moderate | Use with neuron-specific promoter |
| AAV8 | Broad neuronal | 1-2 weeks | Large | Deep brain structures |
| AAV9 | Broad, crosses BBB | 1-2 weeks | Large | Systemic delivery, broad transduction |
| AAVrg | Retrograde neuronal | 2-4 weeks | Projection-specific | Circuit-specific targeting (Tervo et al., 2016) |
Always use a neuron-specific promoter (hSyn, CaMKII) with AAV1/5/8/9, as ubiquitous promoters (CMV, CAG) will also transduce glia (Aschauer et al., 2013).
Standard injection volume: 200-500 nL per site in mice; 1-2 uL per site in rats (Cetin et al., 2006). Standard titer: 1e12 to 5e12 vg/mL (Miyashita et al., 2013). Wait for expression: Minimum 2-3 weeks post-injection; optimal at 3-6 weeks for most AAVs.
Before finalizing a protocol, verify: